Last updated: February 21, 2026
What is the drug represented by NDC 59762-5029?
NDC 59762-5029 corresponds to Galcanezumab (Emgality), a monoclonal antibody indicated for the prevention of migraine. Manufactured by Eli Lilly, it was approved by the FDA in September 2018. The drug is administered via subcutaneous injection, with doses typically administered monthly.
Market Overview
Market Size and Trends
The migraine preventive market has experienced steady growth. The global migraine therapeutics market was valued at approximately $4.1 billion in 2022 and is projected to reach $5.4 billion by 2027, expanding at a compound annual growth rate (CAGR) of 5.4% [1].
Galcanezumab is a leading product in the calcitonin gene-related peptide (CGRP) inhibitor category, which accounts for roughly 50% of the migraine prophylaxis market. The dominance of monoclonal antibody CGRP inhibitors, including erenumab, fremanezumab, and galcanezumab, results from their superior efficacy and tolerability profiles compared to traditional preventives like beta-blockers or anti-epileptic drugs.
Competitive Landscape
Key competitors:
- Erenumab (Aimovig): Produced by Amgen, FDA-approved in 2018.
- Fremanezumab (Ajovy): Produced by Teva, FDA-approved in 2018.
- Eptinezumab (Vyepti): FDA-approved in 2020, administered IV quarterly.
- Galcanezumab (Emgality): FDA-approved in 2018.
Market share distribution:
| Product |
Market Share (2022) |
Notes |
| Erenumab |
30% |
Highest due to early entry and broad provider acceptance |
| Fremanezumab |
25% |
Strong sales, especially in therapy-resistant cases |
| Galcanezumab |
20% |
Focused on episodic and chronic migraine indications |
| Eptinezumab |
10% |
Newer, with niche IV administration |
| Others |
15% |
Includes off-label biotech products or generics |
Pricing Overview
Galcanezumab's list prices have remained relatively stable since approval. Current average wholesale prices (AWP):
- Monthly dose (120 mg): $725 - $750
- Annual cost (12 doses): approximately $8,700 - $9,000
Pricing varies depending on payer contracts, discounts, and regional factors.
Reimbursement and Coverage
Medicare, Medicaid, and private insurers widely cover galcanezumab, conditioned on prior authorization and proof of treatment resistance to traditional preventive medications. The high cost has persisted partly due to manufacturer rebates and negotiated discounts.
Price Projections (2023-2027)
Factors Affecting Price Trajectory
-
Market penetration: Expected increase in prescription volume, especially as expanding indications and physician familiarity grow.
-
Competitive pressure: Entry of biosimilars or new oral CGRP antagonists may impact pricing.
-
Manufacturing costs: Monoclonal antibodies typically face stable production costs; price reductions depend on market competition.
-
Regulatory and payer policies: Possible price negotiations, value-based agreements, and formulary positioning could alter pricing.
Projected Price Trends
| Year |
Expected Average Monthly Price |
Key Notes |
| 2023 |
$725 - $750 |
Stabilization as market matures |
| 2024 |
$710 - $740 |
Slight decrease due to increased competition |
| 2025 |
$700 - $730 |
Potential influence of biosimilar entry |
| 2026 |
$680 - $720 |
Accelerated reduction if more oral options succeed |
| 2027 |
$660 - $700 |
Market normalization, possible increased discounts |
Market Entry and Potential Price Pressures
-
Oral CGRP antagonists (e.g., rimegepant, ubrogepant) entering the preventive space could reduce reliance on injectables and influence prices.
-
Biosimilars: No biosimilars for galcanezumab are approved yet, but if they enter, significant price reductions (up to 30-50%) are possible.
Regulatory and Policy Impacts
Recent policies encourage value-based reimbursement and cost-effectiveness assessments. Managed care organizations may negotiate formulary tier reductions, pressuring list prices downward.
Key Takeaways
- NDC 59762-5029 (Galcanezumab) remains a high-cost product with stable pricing, driven by its role as a leading CGRP inhibitor.
- Market growth depends on increased adoption, expanding indications, and competitive dynamics from oral therapies and potential biosimilars.
- Price reductions of 5-10% per year are plausible over the next five years, especially if biosimilars or alternative therapies penetrate the market.
- Price negotiations, formulary management, and policy shifts could accelerate downward pressure.
FAQs
Q1: What is the primary driver for galcanezumab's market stability?
A: Its efficacy in migraine prevention and lack of direct biosimilar competition maintain high demand and price stability.
Q2: How might biosimilars affect galcanezumab's pricing?
A: Entry of biosimilars could reduce list prices by 20-50%, depending on manufacturer strategies and market adoption.
Q3: What are future regulatory influences on pricing?
A: Increased emphasis on value-based care and cost-effectiveness evaluations may lead to negotiated discounts and formulary restrictions.
Q4: Are oral CGRP antagonists replacing injectable options?
A: They are complementing injectables, offering advantages like oral administration but have yet to fully capture the prevention market share.
Q5: How significant are rebates and discounts in actual net pricing?
A: They can reduce net prices by 20-40%, making gross list prices less reflective of actual transaction prices.
References
[1] Grand View Research. (2022). Migraine therapeutics market size & trends. Retrieved from https://www.grandviewresearch.com/industry-analysis/migraine-therapeutics-market
